REG - Intnl. Biotechnology - Compliance with Market Abuse Regulation

International Biotechnology TrustAnnouncement

11/04/2025 17:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250411:nRSK7769Ea&default-theme=true

RNS Number : 7769E  Intl. Biotechnology Trust PLC  11 April 2025

INTERNATIONAL BIOTECHNOLOGY TRUST PLC

(the "Company")

Compliance with Market Abuse Regulation (MAR)

 

The Company announces that it is satisfied that all inside information which
the Directors and the Company may have in the period leading up to the
announcement of its results for the six months ended 28 February 2025 has
previously been, and will continue to be, notified via a regulatory
information service (RIS). Therefore, the Company is not prohibited from
dealing in its own securities.

 

The mandatory closed period under MAR will last until the results in respect
of the half year ended 28 February 2025 are published, expected to be on, or
around, 13 May 2025.

 

The Company has provided Deutsche Numis, its corporate broker, with a
non-discretionary dealing instruction under which it may undertake share
buybacks if, in the period leading up to the announcement of the half year
results, the Directors of the Company come into the possession of any inside
information.

 

Enquiries:

 

Schroder Investment Management Limited

Kerry Higgins

Tel: 0207 658 6000

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CMCIBMFTMTMBBRA